Setting

Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity

Published: 28 Sep 2020 | Report Code: 10247701 | Pages: 181

Global Pharmacogenomics Market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 88 tables and 83 figures, this 181-page report “Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications.

 

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

 

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure

• Growth Drivers

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Five Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region.

 

Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Genotyping

• SNP Identification

• Diagnostics

• Other Services

 

Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Polymerase Chain Reaction (PCR)

• Microarray

• Sequencing

• Electrophoresis

• Mass Spectrometry

• Other Technologies

 

Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Oncology

• Infectious Diseases

• Neurology/Psychiatry

• Cardiovascular

• Pain Management

• Other Applications

 

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Hospitals and Clinics

• Pharmaceutical Companies

• Research Institutes

 

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

• North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America)

• MEA (Saudi Arabia, UAE, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Technology, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

 

Key Players (this may not be a complete list and extra companies can be added upon request):

23andMe, Inc.

Abbott Laboratories

Admera Health, LLC

Agena Biosciences, Inc.

Astra Zeneca PLC

Bayer AG

Becton, Dickinson and Company

Cancer Genetics, Inc.

Dynamic DNA Laboratories

Empire Genomics LLC

F. Hoffmann-La Roche Ltd

geneOmbio Technologies Pvt Ltd.

Genomic Health, Inc.

Illumina, Inc.

Laboratory Corporation of America Holdings

Myriad Genetics Inc.

Oneome LLC

Opko Health, Inc.

Pathway Genomics Corporation

QIAGEN N.V.

Quest Diagnostics Incorporated

Teva Pharmaceuticals Industries Ltd.

Thermo Fisher Scientific Inc.

Transgenomic, Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:
1 Introduction    8
1.1 Industry Definition and Research Scope    8
1.1.1 Industry Definition    8
1.1.2 Research Scope    10
1.2 Research Methodology    13
1.2.1 Overview of Market Research Methodology    13
1.2.2 Market Assumption    14
1.2.3 Secondary Data    14
1.2.4 Primary Data    14
1.2.5 Data Filtration and Model Design    16
1.2.6 Market Size/Share Estimation    17
1.2.7 Research Limitations    18
1.3 Executive Summary    19
2 Market Overview and Dynamics    22
2.1 Market Size and Forecast    22
2.1.1 Impact of COVID-19 on the Market    26
2.2 Major Growth Drivers    28
2.3 Market Restraints and Challenges    32
2.4 Emerging Opportunities and Market Trends    35
2.5 Porter’s Fiver Forces Analysis    39
3 Segmentation of Global Market by Service    43
3.1 Market Overview by Service    43
3.2 Genotyping    45
3.3 SNP Identification    46
3.4 Diagnostics    47
3.5 Other Services    49
4 Segmentation of Global Market by Technology    50
4.1 Market Overview by Technology    50
4.2 Polymerase Chain Reaction (PCR)    52
4.3 Microarray    53
4.4 Sequencing    54
4.5 Electrophoresis    55
4.6 Mass Spectrometry    56
4.7 Other Technologies    57
5 Segmentation of Global Market by Application    58
5.1 Market Overview by Application    58
5.2 Oncology    60
5.3 Infectious Diseases    61
5.4 Neurology/Psychiatry    62
5.5 Cardiovascular    64
5.6 Pain Management    65
5.7 Other Applications    66
6 Segmentation of Global Market by End User    67
6.1 Market Overview by End User    67
6.2 Hospitals and Clinics    69
6.3 Pharmaceutical Companies    70
6.4 Research Institutes    71
7 Segmentation of Global Market by Region    72
7.1 Geographic Market Overview 2019-2030    72
7.2 North America Market 2019-2030 by Country    78
7.2.1 Overview of North America Market    78
7.2.2 U.S.    82
7.2.3 Canada    86
7.2.4 Mexico    88
7.3 European Market 2019-2030 by Country    90
7.3.1 Overview of European Market    90
7.3.2 Germany    94
7.3.3 UK    96
7.3.4 France    98
7.3.5 Spain    100
7.3.6 Italy    102
7.3.7 Russia    104
7.3.8 Rest of European Market    106
7.4 Asia-Pacific Market 2019-2030 by Country    108
7.4.1 Overview of Asia-Pacific Market    108
7.4.2 Japan    112
7.4.3 China    115
7.4.4 Australia    117
7.4.5 India    119
7.4.6 South Korea    121
7.4.7 Rest of APAC Region    123
7.5 South America Market 2019-2030 by Country    125
7.5.1 Argentina    128
7.5.2 Brazil    130
7.5.3 Chile    132
7.5.4 Rest of South America Market    134
7.6 MEA Market 2019-2030 by Country    135
7.6.1 UAE    138
7.6.2 Saudi Arabia    140
7.6.3 South Africa    142
7.6.4 Other National Markets    144
8 Competitive Landscape    145
8.1 Overview of Key Vendors    145
8.2 New Product Launch, Partnership, Investment, and M&A    149
8.3 Company Profiles    150
23andMe, Inc.    150
Abbott Laboratories    152
Admera Health, LLC    153
Agena Biosciences, Inc.    154
Astra Zeneca PLC    155
Bayer AG    156
Becton, Dickinson and Company    157
Cancer Genetics, Inc.    158
Dynamic DNA Laboratories    159
Empire Genomics LLC    160
F. Hoffmann-La Roche Ltd    161
geneOmbio Technologies Pvt Ltd.    162
Genomic Health, Inc.    163
Illumina, Inc.    164
Laboratory Corporation of America Holdings    165
Myriad Genetics Inc.    166
Oneome LLC    167
Opko Health, Inc.    168
Pathway Genomics Corporation    169
QIAGEN N.V.    170
Quest Diagnostics Incorporated    171
Teva Pharmaceuticals Industries Ltd.    172
Thermo Fisher Scientific Inc.    173
Transgenomic, Inc.    174
9 Investing in Global Market: Risk Assessment and Management    175
9.1 Risk Evaluation of Global Market    175
9.2 Critical Success Factors (CSFs)    178
Related Reports and Products    181

List Of Tables:
Table 1.  Snapshot of Global Pharmacogenomics Market, 2019-2030    20
Table 2. Web-based Resources of Pharmacogenomics    25
Table 3.  Main Product Trends and Market Opportunities in Global Pharmacogenomics Market    35
Table 4. Global Pharmacogenomics Market by Service, 2019-2030, $ mn    43
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing    48
Table 6. Global Pharmacogenomics Market by Technology, 2019-2030, $ mn    50
Table 7. Global Pharmacogenomics Market by Application, 2019-2030, $ mn    58
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry    63
Table 9. Global Pharmacogenomics Market by End User, 2019-2030, $ mn    67
Table 10. Global Pharmacogenomics Market by Region, 2019-2030, $ mn    73
Table 11. Total Health Expenditure per capita in PPP International U.S. Dollars by Country    75
Table 12.  Leading National Pharmacogenomics Market, 2019 and 2030, $ mn    77
Table 13. North America Pharmacogenomics Market by Country, 2019-2030, $ mn    80
Table 14. U.S. Pharmacogenomics Market by Service, 2019-2030, $ mn    84
Table 15. U.S. Pharmacogenomics Market by Technology, 2019-2030, $ mn    84
Table 16. U.S. Pharmacogenomics Market by Application, 2019-2030, $ mn    84
Table 17. Canada Pharmacogenomics Market by Service, 2019-2030, $ mn    87
Table 18. Canada Pharmacogenomics Market by Technology, 2019-2030, $ mn    87
Table 19. Canada Pharmacogenomics Market by Application, 2019-2030, $ mn    87
Table 20. Mexico Pharmacogenomics Market by Service, 2019-2030, $ mn    89
Table 21. Mexico Pharmacogenomics Market by Technology, 2019-2030, $ mn    89
Table 22. Mexico Pharmacogenomics Market by Application, 2019-2030, $ mn    89
Table 23. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn    93
Table 24. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn    95
Table 25. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn    95
Table 26. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn    95
Table 27. UK Pharmacogenomics Market by Service, 2019-2030, $ mn    97
Table 28. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn    97
Table 29. UK Pharmacogenomics Market by Application, 2019-2030, $ mn    97
Table 30. France Pharmacogenomics Market by Service, 2019-2030, $ mn    99
Table 31. France Pharmacogenomics Market by Technology, 2019-2030, $ mn    99
Table 32. France Pharmacogenomics Market by Application, 2019-2030, $ mn    99
Table 33. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn    101
Table 34. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn    101
Table 35. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn    101
Table 36. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn    103
Table 37. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn    103
Table 38. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn    103
Table 39. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn    105
Table 40. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn    105
Table 41. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn    105
Table 42. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn    107
Table 43. APAC Pharmacogenomics Market by Country, 2019-2030, $ mn    110
Table 44. Japan Pharmacogenomics Market by Service, 2019-2030, $ mn    114
Table 45. Japan Pharmacogenomics Market by Technology, 2019-2030, $ mn    114
Table 46. Japan Pharmacogenomics Market by Application, 2019-2030, $ mn    114
Table 47. China Pharmacogenomics Market by Service, 2019-2030, $ mn    116
Table 48. China Pharmacogenomics Market by Technology, 2019-2030, $ mn    116
Table 49. China Pharmacogenomics Market by Application, 2019-2030, $ mn    116
Table 50. Australia Pharmacogenomics Market by Service, 2019-2030, $ mn    118
Table 51. Australia Pharmacogenomics Market by Technology, 2019-2030, $ mn    118
Table 52. Australia Pharmacogenomics Market by Application, 2019-2030, $ mn    118
Table 53. India Pharmacogenomics Market by Service, 2019-2030, $ mn    120
Table 54. India Pharmacogenomics Market by Technology, 2019-2030, $ mn    120
Table 55. India Pharmacogenomics Market by Application, 2019-2030, $ mn    120
Table 56. South Korea Pharmacogenomics Market by Service, 2019-2030, $ mn    122
Table 57. South Korea Pharmacogenomics Market by Technology, 2019-2030, $ mn    122
Table 58. South Korea Pharmacogenomics Market by Application, 2019-2030, $ mn    122
Table 59. Pharmacogenomics Market in Rest of APAC by Country, 2019-2030, $ mn    124
Table 60. South America Pharmacogenomics Market by Country, 2019-2030, $ mn    127
Table 61. Argentina Pharmacogenomics Market by Service, 2019-2030, $ mn    129
Table 62. Argentina Pharmacogenomics Market by Technology, 2019-2030, $ mn    129
Table 63. Argentina Pharmacogenomics Market by Application, 2019-2030, $ mn    129
Table 64. Brazil Pharmacogenomics Market by Service, 2019-2030, $ mn    131
Table 65. Brazil Pharmacogenomics Market by Technology, 2019-2030, $ mn    131
Table 66. Brazil Pharmacogenomics Market by Application, 2019-2030, $ mn    131
Table 67. Chile Pharmacogenomics Market by Service, 2019-2030, $ mn    133
Table 68. Chile Pharmacogenomics Market by Technology, 2019-2030, $ mn    133
Table 69. Chile Pharmacogenomics Market by Application, 2019-2030, $ mn    133
Table 70. MEA Pharmacogenomics Market by Country, 2019-2030, $ mn    137
Table 71. UAE Pharmacogenomics Market by Service, 2019-2030, $ mn    139
Table 72. UAE Pharmacogenomics Market by Technology, 2019-2030, $ mn    139
Table 73. UAE Pharmacogenomics Market by Application, 2019-2030, $ mn    139
Table 74. Saudi Arabia Pharmacogenomics Market by Service, 2019-2030, $ mn    141
Table 75. Saudi Arabia Pharmacogenomics Market by Technology, 2019-2030, $ mn    141
Table 76. Saudi Arabia Pharmacogenomics Market by Application, 2019-2030, $ mn    141
Table 77. South Africa Pharmacogenomics Market by Service, 2019-2030, $ mn    143
Table 78. South Africa Pharmacogenomics Market by Technology, 2019-2030, $ mn    143
Table 79. South Africa Pharmacogenomics Market by Application, 2019-2030, $ mn    143
Table 80. Product Approvals by Company, January 2016 – April 2019    147
Table 81. Breakdown of Global Market by Key Vendor, 2019, 7
Table 82. 23andMe, Inc.: Company Snapshot    150
Table 83. 23andMe, Inc.: Business Segmentation    150
Table 84. 23andMe, Inc.: Product Portfolio    151
Table 85. 23andMe, Inc.: Revenue, 2016-2018, $ mn    151
Table 86. 23andMe, Inc.: Recent Developments    151
Table 87.  Risk Evaluation for Investing in Global Market, 2019-2030    176
Table 88. Critical Success Factors and Key Takeaways    179

List Of Figures:
Figure 1. Research Method Flow Chart    13
Figure 2. Breakdown of Primary Research    15
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation    17
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030    19
Figure 5. Global Pharmacogenomics Market, 2019-2030, $ mn    22
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice    24
Figure 7. Impact of COVID-19 on Business    26
Figure 8. Primary Drivers and Impact Factors of Global Pharmacogenomics Market    28
Figure 9. World Top 10 Causes of Deaths, 2016    31
Figure 10. Primary Restraints and Impact Factors of Global Pharmacogenomics Market    32
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics    34
Figure 12. Investment Opportunity Analysis    36
Figure 13. Porter’s Fiver Forces Analysis of Global Pharmacogenomics Market    39
Figure 14. Breakdown of Global Pharmacogenomics Market by Service, 2019-2030, % of Revenue    43
Figure 15. Global Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)    44
Figure 16. Global Pharmacogenomics Market: Genotyping, 2019-2030, $ mn    45
Figure 17. Global Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn    46
Figure 18. Global Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn    47
Figure 19. Global Pharmacogenomics Market: Other Services, 2019-2030, $ mn    49
Figure 20. Breakdown of Global Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue    50
Figure 21. Global Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)    51
Figure 22. Global Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn    52
Figure 23. Global Pharmacogenomics Market: Microarray, 2019-2030, $ mn    53
Figure 24. Global Pharmacogenomics Market: Sequencing, 2019-2030, $ mn    54
Figure 25. Global Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn    55
Figure 26. Global Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn    56
Figure 27. Global Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn    57
Figure 28. Breakdown of Global Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue    58
Figure 29. Global Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)    59
Figure 30. Global Pharmacogenomics Market: Oncology, 2019-2030, $ mn    60
Figure 31. Global Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn    61
Figure 32. Global Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn    62
Figure 33. Global Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn    64
Figure 34. Global Pharmacogenomics Market: Pain Management, 2019-2030, $ mn    65
Figure 35. Global Pharmacogenomics Market: Other Applications, 2019-2030, $ mn    66
Figure 36. Breakdown of Global Pharmacogenomics Market by End User, 2019-2030, % of Revenue    67
Figure 37. Global Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)    68
Figure 38. Global Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn    69
Figure 39. Global Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn    70
Figure 40. Global Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn    71
Figure 41.  Global Market Snapshot by Region    72
Figure 42.  Geographic Spread of Worldwide Pharmacogenomics Market, 2019-2030, % of Sales Revenue    73
Figure 43. Global Addressable Market Cap in 2020-2030 by Region, Value ($ mn) and Share (%)    74
Figure 44. Health Spending as a Share of GDP by Country, 2015 and 2030    76
Figure 45.  North American Pharmacogenomics Market, 2019-2030, $ mn    79
Figure 46. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue    80
Figure 47. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)    81
Figure 48. U.S. Pharmacogenomics Market, 2019-2030, $ mn    83
Figure 49. Canada Pharmacogenomics Market, 2019-2030, $ mn    86
Figure 50.  Pharmacogenomics Market in Mexico, 2015-2030, $ mn    88
Figure 51.  European Pharmacogenomics Market, 2019-2030, $ mn    91
Figure 52. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue    92
Figure 53. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)    93
Figure 54.  Pharmacogenomics Market in Germany, 2019-2030, $ mn    94
Figure 55.  Pharmacogenomics Market in UK, 2019-2030, $ mn    96
Figure 56.  Pharmacogenomics Market in France, 2019-2030, $ mn    98
Figure 57.  Pharmacogenomics Market in Spain, 2019-2030, $ mn    100
Figure 58.  Pharmacogenomics Market in Italy, 2019-2030, $ mn    102
Figure 59.  Pharmacogenomics Market in Russia, 2019-2030, $ mn    104
Figure 60.  Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn    106
Figure 61. Asia-Pacific Pharmacogenomics Market, 2019-2030, $ mn    109
Figure 62. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue    109
Figure 63. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)    111
Figure 64.  Pharmacogenomics Market in Japan, 2019-2030, $ mn    113
Figure 65.  Pharmacogenomics Market in China, 2019-2030, $ mn    115
Figure 66.  Pharmacogenomics Market in Australia, 2019-2030, $ mn    117
Figure 67.  Pharmacogenomics Market in India, 2019-2030, $ mn    119
Figure 68.  Pharmacogenomics Market in South Korea, 2019-2030, $ mn    121
Figure 69.  Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn    123
Figure 70. South America Pharmacogenomics Market, 2019-2030, $ mn    126
Figure 71. Breakdown of South America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue    126
Figure 72. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)    127
Figure 73.  Pharmacogenomics Market in Argentina, 2019-2030, $ mn    128
Figure 74.  Pharmacogenomics Market in Brazil, 2019-2030, $ mn    130
Figure 75.  Pharmacogenomics Market in Chile, 2019-2030, $ mn    132
Figure 76.  Pharmacogenomics Market in Rest of South America, 2019-2030, $ mn    134
Figure 77. Pharmacogenomics Market in Middle East and Africa (MEA), 2019-2030, $ mn    136
Figure 78. Breakdown of MEA Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue    136
Figure 79. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)    137
Figure 80.  Pharmacogenomics Market in UAE, 2019-2030, $ mn    138
Figure 81.  Pharmacogenomics Market in Saudi Arabia, 2019-2030, $ mn    140
Figure 82.  Pharmacogenomics Market in South Africa, 2019-2030, $ mn    142
Figure 83. Growth Stage of Global Pharmacogenomics Industry over the Forecast Period    145
Key Players (this may not be a complete list and extra companies can be added upon request): 
23andMe, Inc. 
Abbott Laboratories 
Admera Health, LLC 
Agena Biosciences, Inc. 
Astra Zeneca PLC 
Bayer AG 
Becton, Dickinson and Company 
Cancer Genetics, Inc. 
Dynamic DNA Laboratories 
Empire Genomics LLC 
F. Hoffmann-La Roche Ltd 
geneOmbio Technologies Pvt Ltd. 
Genomic Health, Inc. 
Illumina, Inc. 
Laboratory Corporation of America Holdings 
Myriad Genetics Inc. 
Oneome LLC 
Opko Health, Inc. 
Pathway Genomics Corporation 
QIAGEN N.V. 
Quest Diagnostics Incorporated 
Teva Pharmaceuticals Industries Ltd. 
Thermo Fisher Scientific Inc. 
Transgenomic, Inc.